drugset / Trial / NCT03747484
Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer
Phase 1/2
Terminated
7 enrolled
Fred Hutchinson Cancer Center
Affini-T Therapeutics, Inc. · collabNational Cancer Institute (NCI) · collab
Non-randomizedSingle-groupOpen-labelOther
Summary
This phase I/II trial studies the side effects of gene-modified immune cells (FH-MCVA2TCR) and to see how well they work in treating patients with Merkel cell cancer that has spread to other parts of the body (metastatic) or that cannot be removed by surgery (unresectable). Placing a gene that has been created in the laboratory into immune cells may improve the body's ability to fight Merkel cell cancer.
Timeline
- Start
- 2019-07-03
- Primary completion
- 2024-01-09
- Completion
- 2024-01-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FH-MCVA2TCR | Cell therapy | — | Intravenous |
| Background | Avelumab | Monoclonal antibody | — | Intravenous |
| Background | Interferon gamma-1b | Protein / enzyme biologic | 50 ug/m2 | Subcutaneous |
| Background | Pembrolizumab | Monoclonal antibody | — | Intravenous |
Indications
No indication recorded.